centenial surgical suture has closed its trading window for designated persons effective July 1, 2026, to prevent insider trading ahead of its financial results. The window will remain shut until 48 hours after the company disseminates its financial results for the quarter ended June 30, 2026 to the stock exchange. This restriction applies to all designated persons within the organization.

The decision aligns with the Company's Code of Conduct for the prevention of Insider Trading. It is enacted in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and references BSE circular LIST / COMP / 01 / 2019-20 dated April 2, 2019. The closure ensures compliance with regulatory standards designed to maintain market integrity during sensitive periods.

Compliance Details

The closure of the trading window is a standard regulatory procedure implemented before the announcement of quarterly financial outcomes. It prohibits designated persons from buying, selling, or dealing in the company's securities during the specified period.

The intimation was formally communicated to the Department of Corporate Service at BSE Limited. The disclosure was signed and submitted by Mahima Bathwal, Company Secretary & Compliance Officer for Centenial Surgical Suture Ltd.

Centennial Surgical Suture Ltd reported a net loss of ₹220.46 lakh for the financial year ended March 31, 2026, widening from the net loss of ₹146.37 lakh recorded in the previous year. Total income from operations for the fiscal year stood at ₹5400.83 lakh, slightly higher than the ₹5363.63 lakh reported in the prior year. The company's financial performance was impacted by operational challenges, resulting in a basic earnings per share (EPS) of ₹(6.04) for the year.

For the quarter ended March 31, 2026, the company posted a net loss of ₹231.35 lakh, a significant decline from the net loss of ₹118.35 lakh in the corresponding quarter of the previous year. Total income from operations for the quarter decreased to ₹1265.08 lakh from ₹1335.76 lakh in the same period last year. The basic EPS for the quarter stood at ₹(6.34), reflecting the continued pressure on profitability.

The Board of Directors reviewed and approved the standalone audited financial results at a meeting held on May 30, 2026. The results were also reviewed by the Audit Committee prior to the Board's approval. The company disclosed that the financial results are an extract of the detailed format filed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Equity share capital remained unchanged at ₹364.83 lakh for the quarter and year ended March 31, 2026. Reserves, excluding revaluation reserves, were reported at ₹2533.06 lakh for the current year, down from ₹2679.39 lakh in the previous year. The total comprehensive income for the year was ₹(220.46) lakh, mirroring the net loss for the period as there were no other comprehensive income items reported.

Standalone Financial Results

The detailed financial results are available on the company's website and the BSE Limited website. The filing confirms compliance with Regulation 47 of the SEBI (LODR) Regulations, 2015, regarding the publication of audited financial results in newspapers.